Literature DB >> 8699057

Virologic markers of human immunodeficiency virus type 1 in cerebrospinal fluid of infected children.

R D Pratt1, S Nichols, N McKinney, S Kwok, W M Dankner, S A Spector.   

Abstract

To identify virologic correlates associated with central nervous system (CNS) abnormalities in children infected with human immunodeficiency virus type 1 (HIV-1), cerebrospinal fluid (CSF) was examined for virologic markers and correlated with neurodevelopmental status and neuroimaging abnormalities. Of 30 children, 18 (60%) had at least 1 culture-positive CSF sample; in total, 21 (55%) of 38 CSF specimens were culture-positive. CSF white blood cell counts were higher in specimens that were culture-positive (P = .01). HIV-1 RNA was detected in 90% of CSF samples, and RNA levels > or = 10,000 copies/mL were found in 6 (75%) of 8 children with severe neurocognitive impairment (P = .08) and 11 (73%) of 15 children with a cognitive index < or = 85 (P = .04). Higher RNA levels were associated with abnormal brain imaging scans (P = .04) and with neurocognitive deficits (P = .04). Thus, HIV-1 is present within the CNS of most infected children, and neurocognitive impairment appears to be associated with increased HIV-1 replication.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8699057     DOI: 10.1093/infdis/174.2.288

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  New Thoughts on Pathogenesis and Diagnosis of Encephalitis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-06       Impact factor: 3.725

2.  Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches.

Authors:  Pawel Ciborowski
Journal:  Biomark Med       Date:  2009-12       Impact factor: 2.851

3.  Cerebrospinal fluid pleocytosis as a predictive factor for CSF and plasma HIV RNA discordance and escape.

Authors:  Sérgio Monteiro de Almeida; Indianara Rotta; Ana Paula de Pereira; Bin Tang; Anya Umlauf; Cléa Elisa Lopes Ribeiro; Scott Letendre; Ronald J Ellis
Journal:  J Neurovirol       Date:  2020-01-30       Impact factor: 2.643

4.  Sex-based differences in neurocognitive functioning in HIV-infected young adults.

Authors:  Ruxandra Burlacu; Anya Umlauf; Anca Luca; Sara Gianella; Roxana Radoi; Simona M Ruta; Thomas D Marcotte; Luminita Ene; Cristian L Achim
Journal:  AIDS       Date:  2018-01-14       Impact factor: 4.177

5.  Neurocognitive functioning in a Romanian cohort of young adults with parenterally-acquired HIV-infection during childhood.

Authors:  Luminita Ene; Donald R Franklin; Ruxandra Burlacu; Anca E Luca; Andreea G Blaglosov; Ronald J Ellis; Terry J Alexander; Anya Umlauf; Igor Grant; Dan C Duiculescu; Cristian L Achim; Thomas D Marcotte
Journal:  J Neurovirol       Date:  2014-09-04       Impact factor: 2.643

6.  Cognitive and motor deficits associated with HIV-2(287) infection in infant pigtailed macaques: a nonhuman primate model of pediatric neuro-AIDS.

Authors:  J M Worlein; J Leigh; K Larsen; L Kinman; A Schmidt; H Ochs; R J Y Ho
Journal:  J Neurovirol       Date:  2005-02       Impact factor: 2.643

7.  Molecular evidence and clinical significance of herpesvirus coinfection in the central nervous system.

Authors:  Y W Tang; M J Espy; D H Persing; T F Smith
Journal:  J Clin Microbiol       Date:  1997-11       Impact factor: 5.948

8.  Cerebrospinal fluid HIV viral load in different phases of HIV-associated brain disease.

Authors:  Hans-Jürgen von Giesen; Ortwin Adams; Hubertus Köller; Gabriele Arendt
Journal:  J Neurol       Date:  2005-03-06       Impact factor: 4.849

9.  Getting to 90-90-90 in paediatric HIV: What is needed?

Authors:  Mary-Ann Davies; Jorge Pinto; Marlène Bras
Journal:  J Int AIDS Soc       Date:  2015-12-02       Impact factor: 5.396

10.  Biomarkers of HIV-1 associated dementia: proteomic investigation of sera.

Authors:  Jayme Wiederin; Wojciech Rozek; Fenghai Duan; Pawel Ciborowski
Journal:  Proteome Sci       Date:  2009-03-17       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.